PMID- 32539783
OWN - NLM
STAT- MEDLINE
DCOM- 20210409
LR  - 20210409
IS  - 2050-6511 (Electronic)
IS  - 2050-6511 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jun 15
TI  - The effect of exenatide on fasting bile acids in newly diagnosed type 2 diabetes 
      mellitus patients, a pilot study.
PG  - 44
LID - 10.1186/s40360-020-00422-5 [doi]
LID - 44
AB  - BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrated 
      good glycemic efficacy in patients with type 2 diabetes mellitus (T2DM) recent 
      years, whereas studies on GLP-1 RAs' biliary effects were limited. Therefore, we 
      aimed to assess the effect of exenatide on bile acids (BAs) and investigate the 
      role of BAs in the glycemic control effect of exenatide. METHODS: Thirty-eight 
      newly diagnosed T2DM participants without glucose-lowering drugs intake were 
      recruited. Plasma total bile acids in fasting state (FTBAs) and other parameters 
      were tested at baseline. Then exenatide were applied to the T2DM participants for 
      12 weeks. FTBAs and glycemic parameters were measured again after exenatide 
      treatment, and correlation analysis between changes of FTBAs and glycemic 
      parameters were conducted to investigate the role of BAs in the glycemic control 
      effect of exenatide. RESULTS: The baseline FTBAs level of T2DM patients had no 
      significance (3.84 +/- 2.06 vs. 3.87 +/- 2.89, P = 0.954) compared with healthy 
      subjects. After 12-week exenatide treatment for the T2DM patients, FTBAs were 
      decreased from 3.84 +/- 2.06 mumol/L to 3.06 +/- 1.27 mumol/L (P < 0.01). The 
      correlation analysis showed that changes of FTBAs was positively correlated with 
      changes of FPG (r = 0.355, P < 0.05). CONCLUSIONS: Our results demonstrated a 
      decreased FTBAs level after exenatide treatment for 12 weeks, without the 
      interference of metformin and other glucose-lowering drugs. The reduction of 
      FTBAs might not exert a positive role in the glycemic control effect of 
      exenatide. TRIAL REGISTRATION: Trial registration number: NCT04303819. Registered 
      in March 11, 2020 - Retrospectively registered.
FAU - Li, Boyu
AU  - Li B
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 8 
      Gongtinan Road, Chaoyang District, Beijing, 100020, China.
FAU - Hu, Yanjin
AU  - Hu Y
AD  - Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical 
      University, 8 Gongtinan Road, Chaoyang District, Beijing, 100020, China.
FAU - Wang, Guang
AU  - Wang G
AD  - Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical 
      University, 8 Gongtinan Road, Chaoyang District, Beijing, 100020, China. 
      drwg6688@aliyun.com.
FAU - Liu, Lihong
AU  - Liu L
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 8 
      Gongtinan Road, Chaoyang District, Beijing, 100020, China. liulihong@bjcyh.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT04303819
GR  - 81803500/National Natural Science Foundation of China/International
GR  - CYYPY201814/National Outstanding Youth Science Fund Project of National Natural 
      Science Foundation of China (CN)/International
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200615
PL  - England
TA  - BMC Pharmacol Toxicol
JT  - BMC pharmacology & toxicology
JID - 101590449
RN  - 0 (Bile Acids and Salts)
RN  - 0 (Hypoglycemic Agents)
RN  - 9P1872D4OL (Exenatide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Bile Acids and Salts/*metabolism
MH  - Diabetes Mellitus, Type 2/drug therapy/*metabolism
MH  - Exenatide/*pharmacology/therapeutic use
MH  - Fasting/*metabolism
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/*pharmacology/therapeutic use
MH  - Injections, Subcutaneous
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
PMC - PMC7296654
OTO - NOTNLM
OT  - Bile acids
OT  - Exenatide
OT  - Glycemic control
OT  - Type 2 diabetes mellitus
COIS- The authors declare that they have no competing interest.
EDAT- 2020/06/17 06:00
MHDA- 2021/04/10 06:00
PMCR- 2020/06/15
CRDT- 2020/06/17 06:00
PHST- 2020/02/23 00:00 [received]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
PHST- 2020/06/15 00:00 [pmc-release]
AID - 10.1186/s40360-020-00422-5 [pii]
AID - 422 [pii]
AID - 10.1186/s40360-020-00422-5 [doi]
PST - epublish
SO  - BMC Pharmacol Toxicol. 2020 Jun 15;21(1):44. doi: 10.1186/s40360-020-00422-5.